Skip to main content

Mª Ángeles Muchada López

Institutions of which they are part

Main researcher
Stroke research
Vall Hebron Institut de Recerca

Mª Ángeles Muchada López

Institutions of which they are part

Main researcher
Stroke research
Vall Hebron Institut de Recerca

Projects

Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial

IP: Carlos Molina Cateriano
Collaborators: Marta Aurora Rubiera Del Fueyo, David Rodriguez Luna, Mª Ángeles Muchada López
Funding agency: National Health and Medical Res Council (NHMR
Funding: 1950
Reference: TASTE_HMRI2012101
Duration: 19/04/2017 - 16/04/2018

The Chemical Optimization of Cerebral Embolectomy (CHOICE) Trial

IP: Mª Ángeles Muchada López
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 104600
Reference: 20170733
Duration: 01/01/2018 - 31/12/2021

Malalties Neurovasculars (GRC)

IP: Joan Montaner Villalonga
Collaborators: Marta Aurora Rubiera Del Fueyo, Jorge Pagola Pérez Blanca, José Alvarez Sabin, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Marc Ribó Jacobi, Maria Pilar Delgado Martínez, Carlos Molina Cateriano, Anna Rosell Novel, David Rodriguez Luna, Mª Ángeles Muchada López, Estevo Santamarina Pérez, Manuel Quintana Luque
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 48000
Reference: 2014 SGR 686
Duration: 01/01/2014 - 31/12/2016

INVICTUS

IP: Joan Montaner Villalonga
Collaborators: Marta Aurora Rubiera Del Fueyo, Jorge Pagola Pérez Blanca, José Alvarez Sabin, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Marc Ribó Jacobi, Maria Pilar Delgado Martínez, Carlos Molina Cateriano, Anna Rosell Novel, David Rodriguez Luna, Mª Ángeles Muchada López, Estevo Santamarina Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 247695.66
Reference: RD12/0014/0005
Duration: 01/01/2013 - 31/03/2017

Related news

UMBRELLA, a consortium of over 20 public and private partners, kicks off this week with the aim of revolutionising the entire stroke care pathway in Europe by adopting a holistic approach that covers stroke diagnosis, prevention and care.

The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

Related professionals

Santos Ortega, Alba

Santos Ortega, Alba

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Cañas Perea

Xavier Cañas Perea

Director/a d'Àrea
Clinical Research Development Directorate
Read more
Ruiz Esteve, Fernando

Ruiz Esteve, Fernando

Research technician
Neurovascular Diseases
Read more
Marcos Prieto, Susana

Marcos Prieto, Susana

Research technician
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.